Javascript must be enabled to continue!
Mapping Mucormycosis Research: A 25-Year Bibliometric Analysis of Medical Literature
View through CrossRef
Objective: This bibliometric study aimed to analyze global research trends on mucormycosis using medical literature indexed in the Web of Science (WoS) database between 2000 and 2024. Publication output over time, country contributions, international collaboration, funding sources, influential keywords, leading institutions, active journals, and the most cited articles were evaluated.
Materials and Methods: A comprehensive search of Web of Science Core Collection (Science Citation Index Expanded and Emerging Sources Citation Index) was conducted using title-based keywords related to mucormycosis and its etiological agents. English-language articles within the medical domain were included. Statistical analysis was performed using Microsoft Excel, and bibliometric network visualizations were generated with VOSviewer (version 1.6.19).
Results: According to the inclusion and exclusion criteria a total of 2936 publications between 2000 and 2024 were included in the analysis. The number of publications on mucormycosis increased significantly over the past two decades, with pronounced peaks in 2021 and 2022, likely associated with the coronavirus disease 2019 (COVID-19) pandemic. The most frequently cited article was Epidemiology and Clinical Manifestations of Mucormycosis, with 872 citations. The United States, India, and China were the most prolific countries. The University of Texas MD Anderson Cancer Center was the most frequently cited institution, and Cureus was the journal with the highest number of publications. Keyword analysis showed strong associations between mucormycosis and COVID-19, diabetes, and antifungal therapeutics.
Conclusion: The COVID-19 pandemic was associated with a surge of mucormycosis cases and related research activity, particularly among patients with uncontrolled diabetes and those receiving corticosteroid therapy. The growing population of immunocompromised patients and the increasing use of immunosuppressive treatments are likely to continue to drive global research interest in mucormycosis. These findings highlight the need for interdisciplinary and international collaboration to address this emerging public health challenge.
Keywords: Mucormycosis, bibliometric analysis, fungal infections, diabetes, immunocompromised, Rhizopus
Doc Design and Informatics Co. Ltd.
Title: Mapping Mucormycosis Research: A 25-Year Bibliometric Analysis of Medical Literature
Description:
Objective: This bibliometric study aimed to analyze global research trends on mucormycosis using medical literature indexed in the Web of Science (WoS) database between 2000 and 2024.
Publication output over time, country contributions, international collaboration, funding sources, influential keywords, leading institutions, active journals, and the most cited articles were evaluated.
Materials and Methods: A comprehensive search of Web of Science Core Collection (Science Citation Index Expanded and Emerging Sources Citation Index) was conducted using title-based keywords related to mucormycosis and its etiological agents.
English-language articles within the medical domain were included.
Statistical analysis was performed using Microsoft Excel, and bibliometric network visualizations were generated with VOSviewer (version 1.
6.
19).
Results: According to the inclusion and exclusion criteria a total of 2936 publications between 2000 and 2024 were included in the analysis.
The number of publications on mucormycosis increased significantly over the past two decades, with pronounced peaks in 2021 and 2022, likely associated with the coronavirus disease 2019 (COVID-19) pandemic.
The most frequently cited article was Epidemiology and Clinical Manifestations of Mucormycosis, with 872 citations.
The United States, India, and China were the most prolific countries.
The University of Texas MD Anderson Cancer Center was the most frequently cited institution, and Cureus was the journal with the highest number of publications.
Keyword analysis showed strong associations between mucormycosis and COVID-19, diabetes, and antifungal therapeutics.
Conclusion: The COVID-19 pandemic was associated with a surge of mucormycosis cases and related research activity, particularly among patients with uncontrolled diabetes and those receiving corticosteroid therapy.
The growing population of immunocompromised patients and the increasing use of immunosuppressive treatments are likely to continue to drive global research interest in mucormycosis.
These findings highlight the need for interdisciplinary and international collaboration to address this emerging public health challenge.
Keywords: Mucormycosis, bibliometric analysis, fungal infections, diabetes, immunocompromised, Rhizopus.
Related Results
Mucormycosis Research: A global outlook through bibliometric approaches
Mucormycosis Research: A global outlook through bibliometric approaches
Objective. Mucormycosis is a fungal infection in humans where the causative pathogens belong to the order of Mucorales. The fungal pathogens are also known as black fungi based on ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
PB2026 TRANSDIAPHRAGMATIC MUCORMYCOSIS
PB2026 TRANSDIAPHRAGMATIC MUCORMYCOSIS
Background:Mucormycosis is a life‐threatening infection in immunocompromised patients and in haematological malignancy patients in particular.Aims:To report the phenomenon of trans...
The Mycelial Mire-Mucormycosis
The Mycelial Mire-Mucormycosis
Mucormycosis is an infrequent, angio-invasive, fatal fungal infection incriminating immunocompromised individuals.Mucormycosis commonly arises due to infection with rapidly progres...
Is mucormycosis an addition to the pandemic spectrum: An observational study
Is mucormycosis an addition to the pandemic spectrum: An observational study
<p><strong>Abstract:</strong></p>
<p><strong>Introduction and Objective:</strong><br />A concerning increase in occurrences of...
Mucormycosis and role of clinical pharmacologist
Mucormycosis and role of clinical pharmacologist
Mucormycosis (zygomycosis) is a fungal infection (serious but rare) caused by a group of molds called mucoromycetes and it is considered the third most common invasive fungal disea...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...

